TOVX
$0.18-0.01 (-5.36%)
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic...
Recent News
Theriva Biologics receives CHMP scientific advice on VCN-01 Phase 3 design
Theriva Biologics (TOVX) announced the receipt of Scientific Advice from the Committee for Medicinal Products for Human Use of the European Medicines Agency on the design of a Phase 3 clinical trial of lead clinical candidate VCN-01 in combination with gemcitabine/nab-paclitaxel standard-of-care chemotherapy for the first-line treatment of metastatic PDAC. The Company has previously reported the results of the VIRAGE randomized, controlled Phase 2b clinical trial, demonstrating that PDAC patient
Theriva Biologics: Q3 Earnings Snapshot
ROCKVILLE, Md. AP) — Theriva Biologics, Inc. TOVX) on Wednesday reported a loss of $4.4 million in its third quarter.
Theriva Biologics: Q2 Earnings Snapshot
ROCKVILLE, Md. AP) — Theriva Biologics, Inc. TOVX) on Monday reported a loss of $13.1 million in its second quarter.
Theriva Biologics: Q1 Earnings Snapshot
ROCKVILLE, Md. AP) — Theriva Biologics, Inc. TOVX) on Wednesday reported a loss of $4.3 million in its first quarter.